Selected research
Market Structure
Global Multi-Cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Multi-Cancer Early Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Multi-Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Multi-Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Multi-Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Multi-Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Multi-Cancer Early Screening include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Multi-Cancer Early Screening market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Multi-Cancer Early Screening and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Multi-Cancer Early Screening revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Multi-Cancer Early Screening market size, projected growth trends, production technologies, key applications, and end-use industries.
Multi-Cancer Early Screening Segment by Company
Guardant Health
Exact Sciences
Freenome
Epiginomics AG
Bio-techne
ThriveEarlier Detection
GRAIL, Inc.
CellMax life
Berry Genomics
Singlera Genomics
Geneseeq
BGI Genomics
Burning Rock Biotech Limited
New Horizon Health Limited
Yeasen Bio
Hangzhou Aoru Biotech
Amoy Diagnostics Co., Ltd.
Genetron Health
AnchorDx
Surexam Bio-Tech Co.,Ltd.
HaploX
HefeiLaierBiotechnologyCo.,Ltd
Multi-Cancer Early Screening Segment by Type
cfDNA Methylation
Low-pass WGS
Protein Marker Combination
Multi-omics Integrated Analysis
Multi-Cancer Early Screening Segment by Application
Medical Institutions
Physical Examination Centers
Multi-Cancer Early Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multi-Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multi-Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multi-Cancer Early Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Multi-Cancer Early Screening in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multi-Cancer Early Screening industry.
Chapter 3: Detailed analysis of Multi-Cancer Early Screening companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multi-Cancer Early Screeningrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Global Multi-Cancer Early Screening Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032
Table 2. Key Players of cfDNA Methylation
Table 3. Key Players of Low-pass WGS
Table 4. Key Players of Protein Marker Combination
Table 3. Key Players of Multi-omics Integrated Analysis
Table 4. Global Multi-Cancer Early Screening Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032
Table 5. Key Players of Medical Institutions
Table 6. Key Players of Physical Examination Centers
Table 7. Global Multi-Cancer Early Screening Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032
Table 8. Global Multi-Cancer Early Screening Market Size by Region (2021-2026) & (US$ Million)
Table 9. Global Multi-Cancer Early Screening Market Share by Region (2021-2026)
Table 10. Global Multi-Cancer Early Screening Market Size by Region (2027-2032) & (US$ Million)
Table 11. Global Multi-Cancer Early Screening Market Share by Region (2027-2032)
Table 12. Multi-Cancer Early Screening Industry Trends
Table 13. Multi-Cancer Early Screening Industry Drivers
Table 14. Multi-Cancer Early Screening Industry Opportunities and Challenges
Table 15. Multi-Cancer Early Screening Industry Restraints
Table 16. Global Multi-Cancer Early Screening Revenue by Company (US$ Million) & (2021-2026)
Table 17. Global Multi-Cancer Early Screening Revenue Market Share by Company (2021-2026)
Table 18. Global Multi-Cancer Early Screening Players Revenue Ranking, 2024 VS 2025 VS 2026
Table 19. Global Multi-Cancer Early Screening Key Company Head Office and Area Served
Table 20. Global Multi-Cancer Early Screening Company, Product Type & Application
Table 21. Global Multi-Cancer Early Screening Company Establishment Date
Table 22. Global Company Market Concentration Ratio (CR5 and HHI)
Table 23. Global Multi-Cancer Early Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 24. Global Multi-Cancer Early Screening Market Size by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 25. Global Multi-Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million)
Table 26. Global Multi-Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million)
Table 27. Global Multi-Cancer Early Screening Revenue Market Share by Type (2021-2026)
Table 28. Global Multi-Cancer Early Screening Revenue Market Share by Type (2027-2032)
Table 29. Global Multi-Cancer Early Screening Market Size by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 30. Global Multi-Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million)
Table 31. Global Multi-Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million)
Table 32. Global Multi-Cancer Early Screening Revenue Market Share by Application (2021-2026)
Table 33. Global Multi-Cancer Early Screening Revenue Market Share by Application (2027-2032)
Table 34. Guardant Health Company Information
Table 35. Guardant Health Business Overview
Table 36. Guardant Health Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 37. Guardant Health Multi-Cancer Early Screening Product Portfolio
Table 38. Guardant Health Recent Development
Table 39. Exact Sciences Company Information
Table 40. Exact Sciences Business Overview
Table 41. Exact Sciences Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 42. Exact Sciences Multi-Cancer Early Screening Product Portfolio
Table 43. Exact Sciences Recent Development
Table 44. Freenome Company Information
Table 45. Freenome Business Overview
Table 46. Freenome Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 47. Freenome Multi-Cancer Early Screening Product Portfolio
Table 48. Freenome Recent Development
Table 49. Epiginomics AG Company Information
Table 50. Epiginomics AG Business Overview
Table 51. Epiginomics AG Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 52. Epiginomics AG Multi-Cancer Early Screening Product Portfolio
Table 53. Epiginomics AG Recent Development
Table 54. Bio-techne Company Information
Table 55. Bio-techne Business Overview
Table 56. Bio-techne Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 57. Bio-techne Multi-Cancer Early Screening Product Portfolio
Table 58. Bio-techne Recent Development
Table 59. ThriveEarlier Detection Company Information
Table 60. ThriveEarlier Detection Business Overview
Table 61. ThriveEarlier Detection Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 62. ThriveEarlier Detection Multi-Cancer Early Screening Product Portfolio
Table 63. ThriveEarlier Detection Recent Development
Table 64. GRAIL, Inc. Company Information
Table 65. GRAIL, Inc. Business Overview
Table 66. GRAIL, Inc. Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 67. GRAIL, Inc. Multi-Cancer Early Screening Product Portfolio
Table 68. GRAIL, Inc. Recent Development
Table 69. CellMax life Company Information
Table 70. CellMax life Business Overview
Table 71. CellMax life Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 72. CellMax life Multi-Cancer Early Screening Product Portfolio
Table 73. CellMax life Recent Development
Table 74. Berry Genomics Company Information
Table 75. Berry Genomics Business Overview
Table 76. Berry Genomics Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 77. Berry Genomics Multi-Cancer Early Screening Product Portfolio
Table 78. Berry Genomics Recent Development
Table 79. Singlera Genomics Company Information
Table 80. Singlera Genomics Business Overview
Table 81. Singlera Genomics Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 82. Singlera Genomics Multi-Cancer Early Screening Product Portfolio
Table 83. Singlera Genomics Recent Development
Table 84. Geneseeq Company Information
Table 85. Geneseeq Business Overview
Table 86. Geneseeq Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 87. Geneseeq Multi-Cancer Early Screening Product Portfolio
Table 88. Geneseeq Recent Development
Table 89. BGI Genomics Company Information
Table 90. BGI Genomics Business Overview
Table 91. BGI Genomics Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 92. BGI Genomics Multi-Cancer Early Screening Product Portfolio
Table 93. BGI Genomics Recent Development
Table 94. Burning Rock Biotech Limited Company Information
Table 95. Burning Rock Biotech Limited Business Overview
Table 96. Burning Rock Biotech Limited Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 97. Burning Rock Biotech Limited Multi-Cancer Early Screening Product Portfolio
Table 98. Burning Rock Biotech Limited Recent Development
Table 99. New Horizon Health Limited Company Information
Table 100. New Horizon Health Limited Business Overview
Table 101. New Horizon Health Limited Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 102. New Horizon Health Limited Multi-Cancer Early Screening Product Portfolio
Table 103. New Horizon Health Limited Recent Development
Table 104. Yeasen Bio Company Information
Table 105. Yeasen Bio Business Overview
Table 106. Yeasen Bio Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 107. Yeasen Bio Multi-Cancer Early Screening Product Portfolio
Table 108. Yeasen Bio Recent Development
Table 109. Hangzhou Aoru Biotech Company Information
Table 110. Hangzhou Aoru Biotech Business Overview
Table 111. Hangzhou Aoru Biotech Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 112. Hangzhou Aoru Biotech Multi-Cancer Early Screening Product Portfolio
Table 113. Hangzhou Aoru Biotech Recent Development
Table 114. Amoy Diagnostics Co., Ltd. Company Information
Table 115. Amoy Diagnostics Co., Ltd. Business Overview
Table 116. Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 117. Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Product Portfolio
Table 118. Amoy Diagnostics Co., Ltd. Recent Development
Table 119. Genetron Health Company Information
Table 120. Genetron Health Business Overview
Table 121. Genetron Health Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 122. Genetron Health Multi-Cancer Early Screening Product Portfolio
Table 123. Genetron Health Recent Development
Table 124. AnchorDx Company Information
Table 125. AnchorDx Business Overview
Table 126. AnchorDx Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 127. AnchorDx Multi-Cancer Early Screening Product Portfolio
Table 128. AnchorDx Recent Development
Table 129. Surexam Bio-Tech Co.,Ltd. Company Information
Table 130. Surexam Bio-Tech Co.,Ltd. Business Overview
Table 131. Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 132. Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Product Portfolio
Table 133. Surexam Bio-Tech Co.,Ltd. Recent Development
Table 134. HaploX Company Information
Table 135. HaploX Business Overview
Table 136. HaploX Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 137. HaploX Multi-Cancer Early Screening Product Portfolio
Table 138. HaploX Recent Development
Table 139. HefeiLaierBiotechnologyCo.,Ltd Company Information
Table 140. HefeiLaierBiotechnologyCo.,Ltd Business Overview
Table 141. HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 142. HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Product Portfolio
Table 143. HefeiLaierBiotechnologyCo.,Ltd Recent Development
Table 144. North America Multi-Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million)
Table 145. North America Multi-Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million)
Table 146. North America Multi-Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million)
Table 147. North America Multi-Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million)
Table 148. North America Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 149. North America Multi-Cancer Early Screening Market Size by Country (2021-2026)
Table 150. North America Multi-Cancer Early Screening Market Size by Country (2027-2032)
Table 151. Europe Multi-Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million)
Table 152. Europe Multi-Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million)
Table 153. Europe Multi-Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million)
Table 154. Europe Multi-Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million)
Table 155. Europe Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 156. Europe Multi-Cancer Early Screening Market Size by Country (2021-2026)
Table 157. Europe Multi-Cancer Early Screening Market Size by Country (2027-2032)
Table 158. China Multi-Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million)
Table 159. China Multi-Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million)
Table 160. China Multi-Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million)
Table 161. China Multi-Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million)
Table 162. Asia Multi-Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million)
Table 163. Asia Multi-Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million)
Table 164. Asia Multi-Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million)
Table 165. Asia Multi-Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million)
Table 166. Asia Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 167. Asia Multi-Cancer Early Screening Market Size by Country (2021-2026)
Table 168. Asia Multi-Cancer Early Screening Market Size by Country (2027-2032)
Table 169. South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million)
Table 170. South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million)
Table 171. South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million)
Table 172. South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million)
Table 173. South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 174. South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2021-2026)
Table 175. South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2027-2032)
Table 176. Research Programs/Design for This Report
Table 177. Authors List of This Report
Table 178. Secondary Sources
Table 179. Primary Sources
List of Figures
Figure 1. Multi-Cancer Early Screening Product Image
Figure 2. Global Multi-Cancer Early Screening Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million)
Figure 3. Global Multi-Cancer Early Screening Market Share by Type: 2025 VS 2032
Figure 4. cfDNA Methylation Image
Figure 5. Low-pass WGS Image
Figure 6. Protein Marker Combination Image
Figure 7. Multi-omics Integrated Analysis Image
Figure 8. Global Multi-Cancer Early Screening Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million)
Figure 9. Global Multi-Cancer Early Screening Market Share by Application: 2025 VS 2032
Figure 10. Medical Institutions Image
Figure 11. Physical Examination Centers Image
Figure 12. Global Multi-Cancer Early Screening Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 13. Global Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 14. Global Multi-Cancer Early Screening Market Share by Region: 2025 VS 2032
Figure 15. Years Considered
Figure 16. Global Multi-Cancer Early Screening Market Share by Players in 2025
Figure 17. Global Top 5 and 10 Multi-Cancer Early Screening Players Market Share by Revenue in 2025
Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 19. Global Multi-Cancer Early Screening Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 20. Global Multi-Cancer Early Screening Revenue Market Share by Type (2021-2032)
Figure 21. Global Multi-Cancer Early Screening Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 22. Global Multi-Cancer Early Screening Revenue Market Share by Application (2021-2032)
Figure 23. North America Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 24. North America Multi-Cancer Early Screening Market Share by Type (2021-2032)
Figure 25. North America Multi-Cancer Early Screening Market Share by Application (2021-2032)
Figure 26. North America Multi-Cancer Early Screening Market Share by Country (2021-2032)
Figure 27. United States Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 28. Canada Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 29. Mexico Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 30. Europe Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 31. Europe Multi-Cancer Early Screening Market Share by Type (2021-2032)
Figure 32. Europe Multi-Cancer Early Screening Market Share by Application (2021-2032)
Figure 33. Europe Multi-Cancer Early Screening Market Share by Country (2021-2032)
Figure 34. Germany Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 35. France Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 36. U.K. Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 37. Italy Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 38. Russia Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 39. Nordic Countries Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 40. China Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 41. China Multi-Cancer Early Screening Market Share by Type (2021-2032)
Figure 42. China Multi-Cancer Early Screening Market Share by Application (2021-2032)
Figure 43. Asia Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 44. Asia Multi-Cancer Early Screening Market Share by Type (2021-2032)
Figure 45. Asia Multi-Cancer Early Screening Market Share by Application (2021-2032)
Figure 46. Asia Multi-Cancer Early Screening Market Share by Country (2021-2032)
Figure 47. Japan Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 48. South Korea Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 49. Taiwan Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 50. Southeast Asia Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 51. India Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 52. Australia Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 53. South America, Middle East & Africa Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 54. South America, Middle East & Africa Multi-Cancer Early Screening Market Share by Type (2021-2032)
Figure 55. South America, Middle East & Africa Multi-Cancer Early Screening Market Share by Application (2021-2032)
Figure 56. South America, Middle East & Africa Multi-Cancer Early Screening Market Share by Country (2021-2032)
Figure 57. Brazil Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 58. South Africa Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 59. Saudi Arabia Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 60. Turkey Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 61. Argentina Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 62. UAE Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 63. Egypt Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 64. Chile Multi-Cancer Early Screening Market Size (2021-2032) & (US$ Million)
Figure 65. Research Process
Figure 66. Key Executives Interviewed
Scope & coverage.
Types
- cfDNA Methylation
- Low-pass WGS
- Protein Marker Combination
- Multi-omics Integrated Analysis
Applications
- Medical Institutions
- Physical Examination Centers
Companies covered
- Guardant Health
- Exact Sciences
- Freenome
- Epiginomics AG
- Bio-techne
- ThriveEarlier Detection
- GRAIL, Inc.
- CellMax life
- Berry Genomics
- Singlera Genomics
- Geneseeq
- BGI Genomics
- Burning Rock Biotech Limited
- New Horizon Health Limited
- Yeasen Bio
- Hangzhou Aoru Biotech
- Amoy Diagnostics Co., Ltd.
- Genetron Health
- AnchorDx
- Surexam Bio-Tech Co.,Ltd.
- HaploX
- HefeiLaierBiotechnologyCo.,Ltd
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Multi-Cancer Early Screening Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 cfDNA Methylation
- 1.2.3 Low-pass WGS
- 1.2.4 Protein Marker Combination
- 1.2.5 Multi-omics Integrated Analysis
- 1.3 Market Analysis by Application
- 1.3.1 Global Multi-Cancer Early Screening Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Medical Institutions
- 1.3.3 Physical Examination Centers
- 1.4 Global Market Growth Prospects
- 1.5 Global Multi-Cancer Early Screening Growth Trends by Region
- 1.5.1 Global Multi-Cancer Early Screening Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Multi-Cancer Early Screening Market Size by Region (2021-2026)
- 1.5.3 Multi-Cancer Early Screening Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Multi-Cancer Early Screening Market Dynamics
- 2.1 Multi-Cancer Early Screening Industry Trends
- 2.2 Multi-Cancer Early Screening Industry Drivers
- 2.3 Multi-Cancer Early Screening Industry Opportunities and Challenges
- 2.4 Multi-Cancer Early Screening Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Multi-Cancer Early Screening Revenue by Company (2021-2026)
- 3.2 Global Multi-Cancer Early Screening Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Multi-Cancer Early Screening Key Company Head office and Area Served
- 3.4 Global Multi-Cancer Early Screening Company, Product Type & Application
- 3.5 Global Multi-Cancer Early Screening Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Multi-Cancer Early Screening Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Multi-Cancer Early Screening Players Market Share by Revenue in 2025
- 3.6.3 2025 Multi-Cancer Early Screening Tier 1, Tier 2, and Tier 3
4 Multi-Cancer Early Screening Market by Type
- 4.1 Global Multi-Cancer Early Screening Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Multi-Cancer Early Screening Market Size by Type (2021-2032)
- 4.3 Global Multi-Cancer Early Screening Market Size Share by Type (2021-2032)
5 Multi-Cancer Early Screening Market by Application
- 5.1 Global Multi-Cancer Early Screening Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Multi-Cancer Early Screening Market Size by Application (2021-2032)
- 5.3 Global Multi-Cancer Early Screening Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Guardant Health
- 6.1.1 Guardant Health Company Information
- 6.1.2 Guardant Health Business Overview
- 6.1.3 Guardant Health Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Guardant Health Multi-Cancer Early Screening Product Portfolio
- 6.1.5 Guardant Health Recent Developments
- 6.2 Exact Sciences
- 6.2.1 Exact Sciences Company Information
- 6.2.2 Exact Sciences Business Overview
- 6.2.3 Exact Sciences Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Exact Sciences Multi-Cancer Early Screening Product Portfolio
- 6.2.5 Exact Sciences Recent Developments
- 6.3 Freenome
- 6.3.1 Freenome Company Information
- 6.3.2 Freenome Business Overview
- 6.3.3 Freenome Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Freenome Multi-Cancer Early Screening Product Portfolio
- 6.3.5 Freenome Recent Developments
- 6.4 Epiginomics AG
- 6.4.1 Epiginomics AG Company Information
- 6.4.2 Epiginomics AG Business Overview
- 6.4.3 Epiginomics AG Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Epiginomics AG Multi-Cancer Early Screening Product Portfolio
- 6.4.5 Epiginomics AG Recent Developments
- 6.5 Bio-techne
- 6.5.1 Bio-techne Company Information
- 6.5.2 Bio-techne Business Overview
- 6.5.3 Bio-techne Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Bio-techne Multi-Cancer Early Screening Product Portfolio
- 6.5.5 Bio-techne Recent Developments
- 6.6 ThriveEarlier Detection
- 6.6.1 ThriveEarlier Detection Company Information
- 6.6.2 ThriveEarlier Detection Business Overview
- 6.6.3 ThriveEarlier Detection Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 ThriveEarlier Detection Multi-Cancer Early Screening Product Portfolio
- 6.6.5 ThriveEarlier Detection Recent Developments
- 6.7 GRAIL, Inc.
- 6.7.1 GRAIL, Inc. Company Information
- 6.7.2 GRAIL, Inc. Business Overview
- 6.7.3 GRAIL, Inc. Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 GRAIL, Inc. Multi-Cancer Early Screening Product Portfolio
- 6.7.5 GRAIL, Inc. Recent Developments
- 6.8 CellMax life
- 6.8.1 CellMax life Company Information
- 6.8.2 CellMax life Business Overview
- 6.8.3 CellMax life Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 CellMax life Multi-Cancer Early Screening Product Portfolio
- 6.8.5 CellMax life Recent Developments
- 6.9 Berry Genomics
- 6.9.1 Berry Genomics Company Information
- 6.9.2 Berry Genomics Business Overview
- 6.9.3 Berry Genomics Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Berry Genomics Multi-Cancer Early Screening Product Portfolio
- 6.9.5 Berry Genomics Recent Developments
- 6.10 Singlera Genomics
- 6.10.1 Singlera Genomics Company Information
- 6.10.2 Singlera Genomics Business Overview
- 6.10.3 Singlera Genomics Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Singlera Genomics Multi-Cancer Early Screening Product Portfolio
- 6.10.5 Singlera Genomics Recent Developments
- 6.11 Geneseeq
- 6.11.1 Geneseeq Company Information
- 6.11.2 Geneseeq Business Overview
- 6.11.3 Geneseeq Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Geneseeq Multi-Cancer Early Screening Product Portfolio
- 6.11.5 Geneseeq Recent Developments
- 6.12 BGI Genomics
- 6.12.1 BGI Genomics Company Information
- 6.12.2 BGI Genomics Business Overview
- 6.12.3 BGI Genomics Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 BGI Genomics Multi-Cancer Early Screening Product Portfolio
- 6.12.5 BGI Genomics Recent Developments
- 6.13 Burning Rock Biotech Limited
- 6.13.1 Burning Rock Biotech Limited Company Information
- 6.13.2 Burning Rock Biotech Limited Business Overview
- 6.13.3 Burning Rock Biotech Limited Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Burning Rock Biotech Limited Multi-Cancer Early Screening Product Portfolio
- 6.13.5 Burning Rock Biotech Limited Recent Developments
- 6.14 New Horizon Health Limited
- 6.14.1 New Horizon Health Limited Company Information
- 6.14.2 New Horizon Health Limited Business Overview
- 6.14.3 New Horizon Health Limited Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 New Horizon Health Limited Multi-Cancer Early Screening Product Portfolio
- 6.14.5 New Horizon Health Limited Recent Developments
- 6.15 Yeasen Bio
- 6.15.1 Yeasen Bio Company Information
- 6.15.2 Yeasen Bio Business Overview
- 6.15.3 Yeasen Bio Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Yeasen Bio Multi-Cancer Early Screening Product Portfolio
- 6.15.5 Yeasen Bio Recent Developments
- 6.16 Hangzhou Aoru Biotech
- 6.16.1 Hangzhou Aoru Biotech Company Information
- 6.16.2 Hangzhou Aoru Biotech Business Overview
- 6.16.3 Hangzhou Aoru Biotech Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Hangzhou Aoru Biotech Multi-Cancer Early Screening Product Portfolio
- 6.16.5 Hangzhou Aoru Biotech Recent Developments
- 6.17 Amoy Diagnostics Co., Ltd.
- 6.17.1 Amoy Diagnostics Co., Ltd. Company Information
- 6.17.2 Amoy Diagnostics Co., Ltd. Business Overview
- 6.17.3 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Product Portfolio
- 6.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
- 6.18 Genetron Health
- 6.18.1 Genetron Health Company Information
- 6.18.2 Genetron Health Business Overview
- 6.18.3 Genetron Health Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Genetron Health Multi-Cancer Early Screening Product Portfolio
- 6.18.5 Genetron Health Recent Developments
- 6.19 AnchorDx
- 6.19.1 AnchorDx Company Information
- 6.19.2 AnchorDx Business Overview
- 6.19.3 AnchorDx Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 AnchorDx Multi-Cancer Early Screening Product Portfolio
- 6.19.5 AnchorDx Recent Developments
- 6.20 Surexam Bio-Tech Co.,Ltd.
- 6.20.1 Surexam Bio-Tech Co.,Ltd. Company Information
- 6.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
- 6.20.3 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.20.4 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Product Portfolio
- 6.20.5 Surexam Bio-Tech Co.,Ltd. Recent Developments
- 6.21 HaploX
- 6.21.1 HaploX Company Information
- 6.21.2 HaploX Business Overview
- 6.21.3 HaploX Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.21.4 HaploX Multi-Cancer Early Screening Product Portfolio
- 6.21.5 HaploX Recent Developments
- 6.22 HefeiLaierBiotechnologyCo.,Ltd
- 6.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Information
- 6.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
- 6.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.22.4 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Product Portfolio
- 6.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Developments
7 North America
- 7.1 North America Multi-Cancer Early Screening Market Size (2021-2032)
- 7.2 North America Multi-Cancer Early Screening Market Size by Type
- 7.2.1 North America Multi-Cancer Early Screening Market Size by Type (2021-2026)
- 7.2.2 North America Multi-Cancer Early Screening Market Size by Type (2027-2032)
- 7.2.3 North America Multi-Cancer Early Screening Market Share by Type (2021-2032)
- 7.3 North America Multi-Cancer Early Screening Market Size by Application
- 7.3.1 North America Multi-Cancer Early Screening Market Size by Application (2021-2026)
- 7.3.2 North America Multi-Cancer Early Screening Market Size by Application (2027-2032)
- 7.3.3 North America Multi-Cancer Early Screening Market Share by Application (2021-2032)
- 7.4 North America Multi-Cancer Early Screening Market Size by Country
- 7.4.1 North America Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Multi-Cancer Early Screening Market Size by Country (2021-2026)
- 7.4.3 North America Multi-Cancer Early Screening Market Size by Country (2027-2032)
- 7.4.4 North America Multi-Cancer Early Screening Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Multi-Cancer Early Screening Market Size (2021-2032)
- 8.2 Europe Multi-Cancer Early Screening Market Size by Type
- 8.2.1 Europe Multi-Cancer Early Screening Market Size by Type (2021-2026)
- 8.2.2 Europe Multi-Cancer Early Screening Market Size by Type (2027-2032)
- 8.2.3 Europe Multi-Cancer Early Screening Market Share by Type (2021-2032)
- 8.3 Europe Multi-Cancer Early Screening Market Size by Application
- 8.3.1 Europe Multi-Cancer Early Screening Market Size by Application (2021-2026)
- 8.3.2 Europe Multi-Cancer Early Screening Market Size by Application (2027-2032)
- 8.3.3 Europe Multi-Cancer Early Screening Market Share by Application (2021-2032)
- 8.4 Europe Multi-Cancer Early Screening Market Size by Country
- 8.4.1 Europe Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Multi-Cancer Early Screening Market Size by Country (2021-2026)
- 8.4.3 Europe Multi-Cancer Early Screening Market Size by Country (2027-2032)
- 8.4.4 Europe Multi-Cancer Early Screening Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Multi-Cancer Early Screening Market Size (2021-2032)
- 9.2 China Multi-Cancer Early Screening Market Size by Type
- 9.2.1 China Multi-Cancer Early Screening Market Size by Type (2021-2026)
- 9.2.2 China Multi-Cancer Early Screening Market Size by Type (2027-2032)
- 9.2.3 China Multi-Cancer Early Screening Market Share by Type (2021-2032)
- 9.3 China Multi-Cancer Early Screening Market Size by Application
- 9.3.1 China Multi-Cancer Early Screening Market Size by Application (2021-2026)
- 9.3.2 China Multi-Cancer Early Screening Market Size by Application (2027-2032)
- 9.3.3 China Multi-Cancer Early Screening Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Multi-Cancer Early Screening Market Size (2021-2032)
- 10.2 Asia Multi-Cancer Early Screening Market Size by Type
- 10.2.1 Asia Multi-Cancer Early Screening Market Size by Type (2021-2026)
- 10.2.2 Asia Multi-Cancer Early Screening Market Size by Type (2027-2032)
- 10.2.3 Asia Multi-Cancer Early Screening Market Share by Type (2021-2032)
- 10.3 Asia Multi-Cancer Early Screening Market Size by Application
- 10.3.1 Asia Multi-Cancer Early Screening Market Size by Application (2021-2026)
- 10.3.2 Asia Multi-Cancer Early Screening Market Size by Application (2027-2032)
- 10.3.3 Asia Multi-Cancer Early Screening Market Share by Application (2021-2032)
- 10.4 Asia Multi-Cancer Early Screening Market Size by Country
- 10.4.1 Asia Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Multi-Cancer Early Screening Market Size by Country (2021-2026)
- 10.4.3 Asia Multi-Cancer Early Screening Market Size by Country (2027-2032)
- 10.4.4 Asia Multi-Cancer Early Screening Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Multi-Cancer Early Screening Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Type
- 11.2.1 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Multi-Cancer Early Screening Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Application
- 11.3.1 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Multi-Cancer Early Screening Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Country
- 11.4.1 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Multi-Cancer Early Screening Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst